MA43816A - Protéines de liaison inductibles et méthodes d'utilisation - Google Patents
Protéines de liaison inductibles et méthodes d'utilisationInfo
- Publication number
- MA43816A MA43816A MA043816A MA43816A MA43816A MA 43816 A MA43816 A MA 43816A MA 043816 A MA043816 A MA 043816A MA 43816 A MA43816 A MA 43816A MA 43816 A MA43816 A MA 43816A
- Authority
- MA
- Morocco
- Prior art keywords
- inductible
- methods
- binding proteins
- proteins
- binding
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662305092P | 2016-03-08 | 2016-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43816A true MA43816A (fr) | 2018-11-28 |
Family
ID=59789722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043816A MA43816A (fr) | 2016-03-08 | 2017-03-08 | Protéines de liaison inductibles et méthodes d'utilisation |
Country Status (14)
Country | Link |
---|---|
US (1) | US20180134789A1 (fr) |
EP (1) | EP3426689A4 (fr) |
JP (3) | JP7195927B2 (fr) |
KR (2) | KR102501921B1 (fr) |
CN (1) | CN109071667A (fr) |
AU (1) | AU2017229687A1 (fr) |
BR (1) | BR112018068189A2 (fr) |
CA (1) | CA3016165A1 (fr) |
IL (1) | IL261432B2 (fr) |
MA (1) | MA43816A (fr) |
MX (1) | MX2018010824A (fr) |
SG (1) | SG11201807548SA (fr) |
TW (2) | TW202302631A (fr) |
WO (1) | WO2017156178A1 (fr) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016263808B2 (en) | 2015-05-21 | 2019-01-03 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
PT3377103T (pt) | 2015-11-19 | 2021-05-26 | Revitope Ltd | Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
AU2017268460B2 (en) * | 2016-05-20 | 2023-12-14 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
CA3024683A1 (fr) | 2016-05-20 | 2017-11-23 | Harpoon Therapeutics, Inc. | Proteines se liant au fragment monocatenaire variable de cd3 |
WO2018067993A1 (fr) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions et méthodes de reprogrammation des récepteurs des lymphocytes t faisant appel à des protéines de fusion |
CA3044659A1 (fr) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Proteine de liaison a l'antigene membranaire specifique de la prostate |
JP7215997B2 (ja) | 2016-11-23 | 2023-01-31 | ハープーン セラピューティクス,インク. | 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法 |
EP3589662A4 (fr) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | Protéine monovalente inductible de fixation d' antigène |
WO2018160671A1 (fr) * | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inhibiteurs de point de contrôle ciblés et méthodes d'utilisation |
US20200115461A1 (en) * | 2017-05-03 | 2020-04-16 | Harpoon Therapeutics, Inc. | Compositions and methods for adoptive cell therapies |
KR20200026810A (ko) | 2017-05-12 | 2020-03-11 | 하푼 테라퓨틱스, 인크. | Msln 표적화 삼중 특이적 단백질 및 사용 방법 |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
CN111315773A (zh) | 2017-09-08 | 2020-06-19 | 马弗里克治疗公司 | 含有Fc区的条件性活化的结合部分 |
KR20200047687A (ko) * | 2017-09-08 | 2020-05-07 | 매버릭 테라퓨틱스, 인크. | 제약된 조건적으로 활성화된 결합 단백질 |
EA202090739A1 (ru) | 2017-10-13 | 2020-09-07 | Харпун Терапьютикс, Инк. | Белки, связывающие антиген созревания в-клеток |
SG11202003359UA (en) | 2017-10-13 | 2020-05-28 | Harpoon Therapeutics Inc | Trispecific proteins and methods of use |
EP3704151A4 (fr) * | 2017-11-01 | 2021-07-28 | NantBio, Inc. | Voie emt bloquant l'iinterleukine 8 et maîtrisant les cellules souches cancéreuses |
CN110218256B (zh) * | 2018-03-02 | 2020-12-08 | 广西医科大学 | 抗CD3的纳米抗体CD3/Nb29及其制备方法与应用 |
CN110218253B (zh) * | 2018-03-02 | 2020-12-04 | 广西医科大学 | 抗CD3的纳米抗体CD3/Nb14及其制备方法与应用 |
MX2020012217A (es) * | 2018-05-14 | 2021-03-02 | Harpoon Therapeutics Inc | Porción de unión para activación condicional de moléculas de inmunoglobulina. |
WO2019222282A1 (fr) * | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Protéine de liaison activée de manière conditionnelle comprenant un domaine de liaison cible à occlusion stérique |
EP3794022A1 (fr) | 2018-05-14 | 2021-03-24 | Werewolf Therapeutics, Inc. | Polypeptides de cytokine activables et leurs procédés d'utilisation |
SG11202011349PA (en) | 2018-05-14 | 2020-12-30 | Werewolf Therapeutics Inc | Activatable interleukin-2 polypeptides and methods of use thereof |
CN112654633A (zh) * | 2018-06-22 | 2021-04-13 | 科优基因公司 | 基于细胞因子的可生物活化药物及其使用方法 |
US20210309756A1 (en) | 2018-08-09 | 2021-10-07 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
CA3114038A1 (fr) * | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Proteines de liaison a dll3 et methodes d'utilisation |
JP2022523708A (ja) * | 2019-01-29 | 2022-04-26 | グリットストーン バイオ インコーポレイテッド | 多重特異性結合タンパク質 |
CN114173876A (zh) * | 2019-03-05 | 2022-03-11 | 武田药品工业有限公司 | 含有靶向肿瘤抗原的Fc区和部分的条件性活化的结合蛋白质 |
WO2020181140A1 (fr) | 2019-03-05 | 2020-09-10 | Maverick Therapeutics, Inc. | Protéines de liaison à activation conditionnelle limitée |
SG11202112541RA (en) | 2019-05-14 | 2021-12-30 | Werewolf Therapeutics Inc | Separation moieties and methods and use thereof |
WO2021097060A1 (fr) * | 2019-11-13 | 2021-05-20 | Harpoon Therapeutics, Inc. | Molécule pro-immunomodulatrice comprenant une fraction de groupement |
EP4058471A1 (fr) | 2019-11-14 | 2022-09-21 | Werewolf Therapeutics, Inc. | Polypeptides de cytokine activables et leurs méthodes d'utilisation |
US20230075633A1 (en) * | 2019-12-20 | 2023-03-09 | Shandong Boan Biotechnology Co., Ltd. | Optimized anti-cd3 arm in the generation of t-cell bispecific antibodies for immunotherapy |
CN114945597A (zh) * | 2020-01-17 | 2022-08-26 | 艾提欧生物疗法有限公司 | 降低脱靶毒性的前抗体 |
BR112022016550A2 (pt) | 2020-02-21 | 2022-11-16 | Harpoon Therapeutics Inc | Proteínas de ligação a flt3 e métodos de uso |
BR112022019841A2 (pt) | 2020-04-09 | 2022-12-06 | Cytomx Therapeutics Inc | Composições contendo anticorpos ativáveis |
WO2022006562A1 (fr) | 2020-07-03 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Anticorps anti-coronavirus multispécifiques |
IL300598A (en) | 2020-08-17 | 2023-04-01 | Takeda Pharmaceuticals Co | Conditionally activated binding proteins are limited |
CA3184037A1 (fr) * | 2020-08-18 | 2022-02-24 | Onchilles Pharma, Inc. | Proproteines de serine protease modifiee |
JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重car-t組成物及び方法 |
WO2022125576A1 (fr) | 2020-12-09 | 2022-06-16 | Janux Therapeutics, Inc. | Compositions et méthodes associées à des anticorps activés par des tumeurs ciblant psma et des antigènes de cellules effectrices |
KR20230165798A (ko) | 2021-04-06 | 2023-12-05 | 다케다 야쿠힌 고교 가부시키가이샤 | 제약된 조건부 활성화 결합 단백질을 사용한 치료 방법 |
US20240262917A1 (en) | 2021-05-06 | 2024-08-08 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
EP4395812A1 (fr) | 2021-08-31 | 2024-07-10 | Dana-Farber Cancer Institute, Inc. | Compositions et méthodes de traitement de troubles auto-immuns et du cancer |
AU2022396272A1 (en) | 2021-11-24 | 2024-06-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
CA3241395A1 (fr) | 2021-12-17 | 2023-06-22 | Barbel SCHROFELBAUER | Anticorps et leurs utilisations |
CA3241407A1 (fr) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Plateforme pour decouverte d'anticorps |
WO2024039670A1 (fr) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Anticorps anti-cldn4 et leurs méthodes d'utilisation |
WO2024039672A2 (fr) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Anticorps anti-mlsn et leurs méthodes d'utilisation |
WO2024104988A1 (fr) * | 2022-11-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Protéines de liaison recombinantes ayant un domaine effecteur activable |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004242846A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
KR101229731B1 (ko) * | 2003-10-16 | 2013-03-07 | 암젠 리서치 (뮌헨) 게엠베하 | 다중특이적 탈면역화된 cd3-바인더 |
US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
CN103068847B (zh) | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
US20120225081A1 (en) | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
SG10201509588TA (en) * | 2011-05-21 | 2015-12-30 | Macrogenics Inc | CD3-Binding Molecules Capable Of Binding To Human And Non-Human CD3 |
KR20140054009A (ko) | 2011-07-01 | 2014-05-08 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 릴랙신 융합 폴리펩타이드 및 그의 용도 |
IL311502A (en) | 2012-02-27 | 2024-05-01 | Ablynx Nv | CX3CR1 binding polypeptides |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
AU2013224919B2 (en) | 2012-03-01 | 2017-12-07 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
WO2014004549A2 (fr) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Protéines de liaison anti-mésothéline |
MX2015016963A (es) * | 2013-06-10 | 2016-08-08 | Dana Farber Cancer Inst Inc | Metodos y composiciones para reducir la inmunosupresion por celulas de tumor. |
CN111410691B (zh) * | 2014-03-28 | 2024-02-13 | Xencor公司 | 结合至cd38和cd3的双特异性抗体 |
PT3377103T (pt) * | 2015-11-19 | 2021-05-26 | Revitope Ltd | Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas |
US20210309756A1 (en) * | 2018-08-09 | 2021-10-07 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
-
2017
- 2017-03-08 TW TW111119065A patent/TW202302631A/zh unknown
- 2017-03-08 CN CN201780028480.4A patent/CN109071667A/zh active Pending
- 2017-03-08 KR KR1020187029014A patent/KR102501921B1/ko active IP Right Grant
- 2017-03-08 MA MA043816A patent/MA43816A/fr unknown
- 2017-03-08 BR BR112018068189A patent/BR112018068189A2/pt unknown
- 2017-03-08 KR KR1020237005284A patent/KR20230041739A/ko not_active Application Discontinuation
- 2017-03-08 JP JP2018547940A patent/JP7195927B2/ja active Active
- 2017-03-08 IL IL261432A patent/IL261432B2/en unknown
- 2017-03-08 AU AU2017229687A patent/AU2017229687A1/en not_active Abandoned
- 2017-03-08 MX MX2018010824A patent/MX2018010824A/es unknown
- 2017-03-08 TW TW106107861A patent/TW201808990A/zh unknown
- 2017-03-08 WO PCT/US2017/021435 patent/WO2017156178A1/fr active Application Filing
- 2017-03-08 SG SG11201807548SA patent/SG11201807548SA/en unknown
- 2017-03-08 CA CA3016165A patent/CA3016165A1/fr active Pending
- 2017-03-08 EP EP17764037.2A patent/EP3426689A4/fr active Pending
- 2017-10-06 US US15/727,423 patent/US20180134789A1/en not_active Abandoned
-
2022
- 2022-05-18 JP JP2022081366A patent/JP7293456B2/ja active Active
-
2023
- 2023-06-07 JP JP2023093681A patent/JP2023123519A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL261432B2 (en) | 2024-03-01 |
BR112018068189A2 (pt) | 2019-02-05 |
JP7293456B2 (ja) | 2023-06-19 |
EP3426689A1 (fr) | 2019-01-16 |
JP2019513014A (ja) | 2019-05-23 |
JP2023123519A (ja) | 2023-09-05 |
SG11201807548SA (en) | 2018-09-27 |
JP2022140856A (ja) | 2022-09-28 |
RU2018134949A3 (fr) | 2020-08-14 |
IL261432B1 (en) | 2023-11-01 |
TW201808990A (zh) | 2018-03-16 |
IL261432A (en) | 2018-10-31 |
RU2018134949A (ru) | 2020-04-08 |
CA3016165A1 (fr) | 2017-09-14 |
US20180134789A1 (en) | 2018-05-17 |
EP3426689A4 (fr) | 2020-01-15 |
CN109071667A (zh) | 2018-12-21 |
MX2018010824A (es) | 2019-05-15 |
KR20180120245A (ko) | 2018-11-05 |
KR20230041739A (ko) | 2023-03-24 |
WO2017156178A1 (fr) | 2017-09-14 |
AU2017229687A1 (en) | 2018-09-20 |
KR102501921B1 (ko) | 2023-02-21 |
JP7195927B2 (ja) | 2022-12-26 |
TW202302631A (zh) | 2023-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43816A (fr) | Protéines de liaison inductibles et méthodes d'utilisation | |
FR24C1033I1 (fr) | Molécules se liant à pd-1 et méthodes d'utilisation correspondantes | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
IL281783A (en) | SIRPa type binding proteins and methods of using them | |
IL261666A (en) | Related proteins and methods of using them | |
MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
MA48579A (fr) | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci | |
MA49288A (fr) | Reactifs particulaires oligomères et leurs méthodes d'utilisation | |
EP3635013A4 (fr) | Protéines de liaison à la nectine-4 et leurs procédés d'utilisation | |
MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
MA47113A (fr) | Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation | |
MA43823A (fr) | Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation | |
MA44670A (fr) | Protéines de liaison trispécifiques et/ou trivalentes | |
MA42446A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MA40069A (fr) | Molécules de liaison trispécifiques et leurs procédés d'utilisation | |
MA43385A (fr) | Nouveaux anticorps anti-claudine et méthodes d'utilisation | |
MA41414A (fr) | Protéines de liaison agonistes d' icos | |
MA42428A (fr) | Anticorps humanisés et à maturation d'affinité dirigés contre fcrh5 et méthodes d'utilisation | |
MA55472A (fr) | Molécules de liaison de lymphopoïétine stromale thymique (tslp) et procédés d'utilisation des molécules | |
MA41313A (fr) | Anticorps de liaison de la protéine april modifiés | |
MA44526A (fr) | Oxystérols et leurs méthodes d'utilisation | |
MA46422A (fr) | Oligonucléotides modifiés et méthodes d'utilisation | |
ZA201900209B (en) | Novel natural protein and application thereof |